Clinical Observation Of Fuyang Qiangzhuang Moxibustion On Patients With Ardvanced NSCLC,T Lymphocyte Subsets And Quality Of Life

Objective:This research aims at strong moxibustion combined with standardized chemotherapy,to explore the strong moxibustion on advanced non-small cell lung cancer(Non-small-cell lung,cancer,NSCLC)T lymphocyte subsets in patients with chemotherapy related indicators,and influence the quality of life,as the auxiliary treatment of cancer and provide a new way.Methods:From July 2015 to June 2016,67 cases of B III ~ IV NSCLC patients were randomly divided into experimental group and control group,34 cases in the observation group,33 cases in the control group,the two groups with GP(gemcitabine + cisplatin)chemotherapy,the observation group on the basis of the control group,with Fuyang Qiangzhuang moxibustion.Fuyang Qiangzhuang moxibustion point: Moxibustion Zusanli(double),Guan Yuan,Qihai,Feishu(double),Pishu(double),Shenshu(double),Gaohuang(double).Supine points(Zusanli,Guan Yuan,Qihai,)and prone position(Feishu,Pishu,Shenshu,Gaohuang),In the above-mentioned points with Monkshood cake-separated moxibustion.once every other day,alternating moxibustion.The two groups of patients continued to use the drug for 4 cycles,observed the treatment effect of the patients in the two groups,the score of TCM syndromes before and after treatment,KPS score,weight,quality of life,clinical T lymphocyte subsets and safety indicators.Results:1.The short-term efficacy of the two groups were compared,by statistical analysis,no significant difference(P>0.05).2.The efficacy of TCM Syndromes of the two groups were compared,the rank sum test,the experimental group was higher than the control group(P<0.05).3.The weight change and quality of life of the two groups were compared,the experimental group was better than the control group(P<0.05).4.T lymphocyte subsets before and after treatment in two groups: CD3+,CD4+ and CD4+/CD8+ in the two groups were higher than those before treatment(P < 0.05),CD8+was lower than that before treatment(P < 0.05).After treatment,CD3+,CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group(P <0.05),and CD8+ was lower than that of the control group(P < 0.05).5.Safety evaluation: The decrease of WBC,HB,PLT,constipation,nausea and vomiting in the experimental group were lower than those in the control group(p<0.05),and there was no significant difference in the incidence of ALT and Scr in the two groups(P>0.05).Conclusion:Fuyang Qiangzhuang moxibustion combined with GP(gemcitabine + cisplatin)chemotherapy regimen for advanced NSCLC in the near future curative effect and chemotherapy effect.But in improving the quality of life of patients,improve immune function,reduce the incidence of side effects such as white blood cell,hemoglobin,thrombocytopenia,nausea and vomiting in the experimental group than the control group.Fuyang Qiangzhuang moxibustion combined with chemotherapy in the treatment of advanced non-small cell lung cancer is effective,low toxicity,worthy of clinical promotion.